Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Sell
27
QURE Quote, Financials, Valuation and Earnings
Last price:
$12.36
Seasonality move
:
6.53%
Day range:
$10.05 - $11.62
52-week range:
$3.73 - $19.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.05x
P/B ratio:
9.53x
Volume:
4.4M
Avg. volume:
2.2M
1-year change:
108.71%
Market cap:
$544M
Revenue:
$27.1M
EPS (TTM):
-$4.93
Analysts' Opinion
-
Consensus RatinguniQure NV has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.45, uniQure NV has an estimated upside of 252.37% from its current price of $10.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing -29.19% downside risk from its current price of $10.06.
Fair Value
-
According to the consensus of 11 analysts, uniQure NV has 252.37% upside to fair value with a price target of $35.45 per share.
QURE vs. S&P 500
-
Over the past 5 trading days, uniQure NV has underperformed the S&P 500 by -31.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
uniQure NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
uniQure NV revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter uniQure NV reported revenues of $5.2M.
Earnings Growth
-
uniQure NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter uniQure NV reported earnings per share of -$1.50.
Enterprise value:
227.8M
EV / Invested capital:
--
Price / LTM sales:
18.05x
EV / EBIT:
--
EV / Revenue:
8.40x
PEG ratio (5yr expected):
-0.66x
EV / Free cash flow:
-1.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.8M
Return On Assets:
-33.88%
Net Income Margin (TTM):
-883.35%
Return On Equity:
-239.27%
Return On Invested Capital:
-131.71%
Operating Margin:
-813.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $106.5M | $15.8M | $27.1M | $6.7M | $5.2M | |
| Gross Profit | $103.1M | $2.2M | $8.8M | -$2.1M | $4.6M | |
| Operating Income | -$143.9M | -$282.3M | -$180.9M | -$61.2M | -$42.5M | |
| EBITDA | -$108M | -$253.1M | -$160.7M | -$50.3M | -$53.2M | |
| Diluted EPS | -$2.71 | -$6.48 | -$4.93 | -$1.53 | -$1.50 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $258.9M | $628.2M | $476.8M | $651.9M | $390.3M | |
| Total Assets | $340.4M | $809.2M | $705M | $831.7M | $556.5M | |
| Current Liabilities | $27.3M | $36.8M | $75.9M | $73.7M | $40.1M | |
| Total Liabilities | $96.5M | $213.4M | $229M | $624M | $563.3M | |
| Total Equity | $243.9M | $595.8M | $476M | $207.7M | -$6.8M | |
| Total Debt | $35.6M | $101M | $102.8M | $101.7M | $51.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$145.1M | -$145.9M | -$182.7M | -$49.5M | -$52.8M | |
| Cash From Investing | -$182.7M | -$205.7M | $163M | $59.6M | -$26.6M | |
| Cash From Financing | $1.4M | $362.7M | -$59.5M | $46K | -$6.5M | |
| Free Cash Flow | -$162.7M | -$153.1M | -$194.4M | -$51.6M | -$52.9M | |
QURE
Sector
Market Cap
$544M
$34.5M
Price % of 52-Week High
52.45%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
0.91%
-0.79%
1-Year Price Total Return
108.71%
-42.08%
Beta (5-Year)
0.099
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.72
200-day SMA
Sell
Level
$10.06
Bollinger Bands (100)
Sell
Level
11.27 - 16.29
Chaikin Money Flow
Buy
Level
46.4M
20-day SMA
Sell
Level
$12.41
Relative Strength Index (RSI14)
Sell
Level
38.85
ADX Line
Sell
Level
29.47
Williams %R
Buy
Level
-99.8374
50-day SMA
Sell
Level
$12.28
MACD (12, 26)
Buy
Level
0.36
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
137.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.1452)
Sell
CA Score
(Annual)
Level (-3.2078)
Buy
Beneish M-Score
(Annual)
Level (-2.4578)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.7973)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Stock Forecast FAQ
In the current month, QURE has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The QURE average analyst price target in the past 3 months is $35.45.
-
Where Will uniQure NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that uniQure NV share price will rise to $35.45 per share over the next 12 months.
-
What Do Analysts Say About uniQure NV?
Analysts are divided on their view about uniQure NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that uniQure NV is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is uniQure NV's Price Target?
The price target for uniQure NV over the next 1-year time period is forecast to be $35.45 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is QURE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for uniQure NV is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of QURE?
You can purchase shares of uniQure NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase uniQure NV shares.
-
What Is The uniQure NV Share Price Today?
uniQure NV was last trading at $12.36 per share. This represents the most recent stock quote for uniQure NV. Yesterday, uniQure NV closed at $10.06 per share.
-
How To Buy uniQure NV Stock Online?
In order to purchase uniQure NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
